COMMUNIQUÉS West-GlobeNewswire

Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
01/07/2019
Basel, Switzerland, July 01, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient was enrolled in a newly opened cohort in the ongoing FIDES-01 phase 2 registrational study with the [...]
Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model
01/07/2019
Data Supports Therapeutic Role of GKT831 in Advanced Liver Fibrosis Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis ARCHAMPS, [...]
Le GKT831 de Genkyotex prévient de multiples complications de l’hypertension portale dans un modèle préclinique
01/07/2019
Les données confirment le rôle thérapeutique du GKT831 dans la fibrose avancée du foie Résultats publiés dans Clinics and Research in Hepatology and Gastroenterology Un essai de Phase 3 est envisagé dans la cholangite [...]
ASIT Biotech Continues its Transformation From Research to Late Stage Clinical Development
01/07/2019
Company shareholders approve all motions at Extraordinary General Meeting Firm expects to raise €9-12 M to finance focused development Jean-Paul Prieels confirmed as new member of Board of Directors Phase III on track [...]
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
01/07/2019
Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
Inspirotec advances “Exhale” product business expansion
01/07/2019
CHICAGO, June 30, 2019 (GLOBE NEWSWIRE) -- Inspirotec Inc., is a rapidly growing Chicago-based company with it’s Exhale™ highly portable whole house allergen measuring system and remediation support services. Exhale™ is [...]
ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business.
30/06/2019
ESPERITE N.V. (ESP) publishes its half-year report. Revenues, results and consolidated equity were impacted by adverse market conditions on the stem cell business. CEO, Frédéric Amar, has converted part of his loan [...]
Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
29/06/2019
SOUTH SAN FRANCISCO, Calif., June 29, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy
29/06/2019
Label update includes data from four clinical studies including long-term safety and efficacy data across a broad Spinal Muscular Atrophy (SMA) population Data from over 300 patients across a broad range of ages and [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06/2019
CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019, that were previously [...]
MedMira Reports Third Quarter Results
29/06/2019
HALIFAX, Nova Scotia, June 28, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2019. Q3 FY2019 Financial Results Highlights Profit and [...]
Esperite N.V.: Update to the market on the publication of the Annual Report 2018
28/06/2019
Esperite N.V. (ESP): Update to the market on the publication of the Annual Report 2018 Amsterdam, The Netherlands – 28 June 2019 Esperite N.V. announced on 30 April 2019 that the publication of the Annual Report 2018 [...]
RavenQuest Completes Non-Brokered Private Placement
28/06/2019
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS VANCOUVER, British Columbia, June [...]
Tower One Provides Operational Update, Amends Existing Warrants and Issues New Warrants
28/06/2019
VANCOUVER, British Columbia, June 28, 2019 (GLOBE NEWSWIRE) -- Tower One Wireless Corp (CSE: TO) (OTCMKTS: TOWTF) (Frankfurt: A2DKQ4 ) (“Tower One” or the “Company ”) announces an operations update with the execution of [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/06/2019
CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Chr. Hansen Holding A/S - Major shareholder announcement from The Capital Group Companies, Inc.
28/06/2019
Company announcement No. 12/2019 June 28, 2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 [...]
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
28/06/2019
Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, [...]
MRI Interventions, Inc. Announces Uplisting to NYSE American
28/06/2019
Stock Will Trade Under Its Existing Symbol ‘MRIC’ Starting July 3, 2019 IRVINE, Calif., June 28, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) (the “ Company ”) today announced that its common stock has [...]
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/06/2019
CHICAGO, June 28, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]

Pages